| Type | Public |
|---|---|
| Industry | Pharmaceuticals |
| Founded | Singapore (2002) |
| Founder(s) | Professor Claude Wischik Dr K. M. Seng |
| Headquarters | Singapore |
| Key people | Professor Claude Wischik, Executive Chairman Dr Shay Way Seng, Managing Director John Harry, Lead Pharmaceutical Strategist |
| Website | TauRx Therapeutics |
TauRx Therapeutics Ltd is a startup pharmaceutical company that is based in Singapore.[1]
The company was founded in 2002 by the late gynecologist, surgeon and venture capitalist K. M. Seng and the research biologist Claude Wischik who is currently its CEO.
In 1988 Wischik and coworkers discovered that abnormal fibres of tau protein form inside nerve cells in patients with Alzheimer disease, and that their aggregation correlatates to the development of dementia. The company has focused on the development of drugs that dissolve tau fibres in an attempt to manage patients with Alzheimer. Rember is an investigational drug for this purpose by TauRx Therapeutics.[2]